論文・総説 - 稲澤　譲治

101. Matsumoto H, Zaha K, Nakamura Y, Hayashi S, Inazawa J, Nonoyama S. Chromosome 9q33q34 microdeletion with early infantile epileptic encephalopathy, severe　dystonia, abnormal eye movements, and nephroureteral malformations Pediatr　Neurol. 2014.07; 51 (1): 1196-1206.

102. Matsumoto H, Zaha K, Nakamura Y, Hayashi S, Inazawa J, Nonoyama S. Chromosome 9q33q34 microdeletion with early infantile epileptic encephalopathy, severe dystonia, abnormal eye movements, and nephroureteral malformations. Pediatric neurology. 2014.07; 51 (1): 170-5. ( PubMed, DOI )

103. Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A, Aoki D, Inazawa J. High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer Acta Histochem Cytochem. 2014.06; 47 (6): 295-301.

104. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014.02; 370 (7): 632-639. ( PubMed, DOI )

105. Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, Uchida K, Inoue J, Inazawa J, Kawano T, Board PG. γ-Glutamylcyclotransferase as a novel immunohistochemical biomarker for the malignancy of esophageal squamous tumors. Hum Pathol. 2014.02; 45 (2): 331-341. ( PubMed, DOI )

106. Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J. The Impact of miRNA-Based Molecular Diagnostics and Treatment of NRF2-Stabilized Tumors. Mol Cancer Res. 2014.01; 12 (1): 58-68. ( PubMed, DOI )

107. Dobashi Y, Sato E, Oda Y, Inazawa J, Ooi A. Significance of Akt activation and AKT gene increases in soft tissue tumors. Hum Pathol. 2014.01; 45 (1): 127-136. ( PubMed, DOI )

108. Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S. NF-κB Inducing Kinase, a Central Signaling Component of the Non-Canonical Pathway of NF-κB, Contributes to Ovarian Cancer Progression. PLoS ONE. 2014; 9 (2): e88347. ( PubMed, DOI )

109. Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A, Aoki D, Inazawa J. High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. Acta histochemica et cytochemica. 2014; 47 (6): 295-301. ( PubMed, DOI )

110. Yamamoto Y, Konishi H, Ichikawa D, Arita T, Shoda K, Komatsu S, Shiozaki A, Ikoma H, Fujiwara H, Okamoto K, Ochiai T, Inoue J, Inazawa J, Otsuji E. Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma. Oncol Rep. 2013.10; 30 (4): 1687-1694. ( PubMed, DOI )

111. Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J, Kozaki K. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis. 2013.03; 34 (3): 560-569. ( PubMed, DOI )

112. Miyawaki Y, Imoto I, Tokairin Y, Kawada K, Nakajima Y, Nishikage T, Nagai K, Kajiwara M, Inazawa J, Kawano T. Esophageal squamous cell carcinoma developed 11 years after allogeneic bone marrow transplantation for acute lymphatic leukemia. Jpn J Clin Oncol. 2013.01; 43 (1): 69-73. ( PubMed, DOI )

113. Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS ONE. 2013; 8 (10): e76463. ( PubMed, DOI )

114. Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K. miR-655 Is an EMT-Suppressive MicroRNA Targeting ZEB1 and TGFBR2. PLoS One. 2013; 8 (5): e62757. ( PubMed, DOI )

115. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One. 2013; 8 (3): e60155. ( PubMed, DOI )

116. Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J, Ooi A. Molecular alterations in AKT and its protein activation in human lung carcinomas. Hum Pathol. 2012.12; 43 (12): 2229-2240. ( PubMed, DOI )

117. Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, Maruyama K, Mizuno S, Shimakawa S, Ono H, Oyanagi R, Kubo S, Barkovich AJ, Inazawa J. Clinical and radiological features of Japanese patients with a severe phenotype due to CASK mutations. Am J Med Genet A. 2012.12; 158A (12): 3112-3118. ( PubMed, DOI )

118. Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, Inazawa J, Golden A, Carey DJ, Farooq A, Tromp G, Sudol M. Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene. 2012.11; 509 (2): 215-222. ( PubMed, DOI )

119. Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, Muramatsu T, Sugihara K, Inazawa J. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene. 2012.11; 31 (47): 4923-4934. ( PubMed, DOI )

120. Bai H, Inoue J, Kawano T, Inazawa J. A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers. Oncogene. 2012.10; 31 (40): 4397-4408. ( PubMed, DOI )